tirzepatide news 2025 BIG for Zepbound patients! 🚨 Eli Lilly just announced additional single-dose vials of Zepbound® (tirzepatide), making it more accessible for self-pay patients. With the new Zepbound Self Pay Journey Program, pricing New drug tirzepatide delivers significant

These predispositions are not diagnostic but may provide clinical context for provider conversations about medication selection and realistic outcome timelines

We find that haploinsufficiency for SLC25A51 lowers mitochondrial NAD + and impairs regeneration despite unchanged whole-tissue NAD + levels and, conversely, that overexpression of SLC25A51 raises mitochondrial NAD + content and improves regeneration comparably with the effect of systemic NAD + precursor supplementation

Autoimmun Rev 9(2):113116 Fischer J, Kleinau G, Rutz C et al (2018) Evidence of G-protein-coupled receptor and substrate transporter heteromerization at a single molecule level

Table of Contents Eli Lilly said, on March 12, 2026, it had notified the US Food and Drug Administration about an impurity found in compounded tirzepatide products mixed with vitamin B12, based on testing of 10 samples obtained from compounding pharmacies, medspas, and telehealth networks